CN115279347A - Ahr抑制剂和其用途 - Google Patents

Ahr抑制剂和其用途 Download PDF

Info

Publication number
CN115279347A
CN115279347A CN202080092187.6A CN202080092187A CN115279347A CN 115279347 A CN115279347 A CN 115279347A CN 202080092187 A CN202080092187 A CN 202080092187A CN 115279347 A CN115279347 A CN 115279347A
Authority
CN
China
Prior art keywords
cancer
compound
sdi
patient
pharmaceutically acceptable
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
CN202080092187.6A
Other languages
English (en)
Chinese (zh)
Inventor
A·C·卡斯特罗
J·M·诺兰三世
X·M·张
J·塞格
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Ekina Oncology
Original Assignee
Ekina Oncology
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ekina Oncology filed Critical Ekina Oncology
Publication of CN115279347A publication Critical patent/CN115279347A/zh
Withdrawn legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/2027—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/53—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with three nitrogens as the only ring hetero atoms, e.g. chlorazanil, melamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Polysaccharides And Polysaccharide Derivatives (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
CN202080092187.6A 2019-11-26 2020-11-25 Ahr抑制剂和其用途 Withdrawn CN115279347A (zh)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201962940514P 2019-11-26 2019-11-26
US62/940,514 2019-11-26
US202063106530P 2020-10-28 2020-10-28
US63/106,530 2020-10-28
PCT/US2020/062116 WO2021108469A1 (en) 2019-11-26 2020-11-25 Ahr inhibitors and uses thereof

Publications (1)

Publication Number Publication Date
CN115279347A true CN115279347A (zh) 2022-11-01

Family

ID=73856333

Family Applications (1)

Application Number Title Priority Date Filing Date
CN202080092187.6A Withdrawn CN115279347A (zh) 2019-11-26 2020-11-25 Ahr抑制剂和其用途

Country Status (11)

Country Link
US (1) US20230026232A1 (enExample)
EP (1) EP4065090A1 (enExample)
JP (1) JP2023503167A (enExample)
KR (1) KR20220125232A (enExample)
CN (1) CN115279347A (enExample)
AU (1) AU2020391451A1 (enExample)
BR (1) BR112022010143A2 (enExample)
CA (1) CA3159315A1 (enExample)
IL (1) IL293325A (enExample)
MX (1) MX2022006312A (enExample)
WO (1) WO2021108469A1 (enExample)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MX2019012431A (es) 2017-04-21 2020-08-03 Ikena Oncology Inc Inhibidores del receptor de hidrocarburos de arilo (ahr) de indol y usos de los mismos.
AU2020394424A1 (en) 2019-11-26 2022-06-16 Ikena Oncology, Inc. Polymorphic carbazole derivatives and uses thereof
WO2021236717A1 (en) 2020-05-20 2021-11-25 Senda Biosciences, Inc. Fused imidazole derivatives as ahr antagonists
TW202421150A (zh) * 2022-09-14 2024-06-01 美商阿克思生物科學有限公司 艾魯美冷之分散體

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB201103837D0 (en) * 2011-03-07 2011-04-20 Oxagen Ltd Amorphous (5-Fluoro-2-Methyl-3-Quinolin-2-Ylmethyl-Indol-1-Yl)-acetic acid
MX2019012431A (es) 2017-04-21 2020-08-03 Ikena Oncology Inc Inhibidores del receptor de hidrocarburos de arilo (ahr) de indol y usos de los mismos.
EP3774767B1 (en) * 2018-04-05 2025-10-29 Beth Israel Deaconess Medical Center, Inc. Aryl hydrocarbon receptor modulators and uses thereof
KR20210151061A (ko) * 2019-03-11 2021-12-13 피티씨 테라퓨틱스, 인크. 향상된 생체이용률을 갖는 화합물 형태 및 이의 제형

Also Published As

Publication number Publication date
AU2020391451A1 (en) 2022-06-16
EP4065090A1 (en) 2022-10-05
WO2021108469A1 (en) 2021-06-03
CA3159315A1 (en) 2021-06-03
IL293325A (en) 2022-07-01
KR20220125232A (ko) 2022-09-14
MX2022006312A (es) 2022-06-22
BR112022010143A2 (pt) 2022-08-09
JP2023503167A (ja) 2023-01-26
US20230026232A1 (en) 2023-01-26

Similar Documents

Publication Publication Date Title
JP7022172B2 (ja) ２－（ｔｅｒｔ－ブチルアミノ）－４－（（１Ｒ，３Ｒ，４Ｒ）－３－ヒドロキシ－４－メチルシクロヘキシルアミノ）－ピリミジン－５－カルボキサミドの製剤
US7988994B2 (en) Capsule formulation of pirfenidone and pharmaceutically acceptable excipients
EP3435985B1 (en) Granulate formulation of 5-methyl-1-phenyl-2(1h)-pyridone and method of making the same
EP3125872B1 (en) Amorphous solid dispersion comprising taxane, tablet comprising the same, and method for preparing the same
CN109069410A (zh) 用于治疗血液恶性肿瘤和实体瘤的idh1抑制剂
US20230026232A1 (en) Ahr inhibitors and uses thereof
JP2022524424A (ja) 向上したバイオアベイラビリティを有する化合物形態及びその製剤
KR20130078147A (ko) 일정한 입도를 갖는 ４，５―디아릴―３（２ｈ）―퓨라논 유도체를 포함하는 약학 조성물
BR122023016197B1 (pt) Sal cristalino de 2-(terc-butilamino)-4-((1r,3r,4r)-3-hidroxi-4-metilciclohexilamino)-pirimidina-5-carboxamida, composição farmacêutica o compreendendo e uso dos mesmos

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
WW01 Invention patent application withdrawn after publication

Application publication date: 20221101

WW01 Invention patent application withdrawn after publication